Reversal of Factor Xa Inhibitor-Related Intracranial Hemorrhage: A Multicenter, Retrospective, Observational Study Comparing the Efficacy and Safety of Andexanet and PCCs
This study compared patients with a wide variety of intracranial hemorrhage types taking direct oral anticoagulants (e.g. apixaban or rivaroxaban) who then received andexanet versus prothrombin complex concentrates (PCCs)
Patients receiving andexanet (87.8%) had higher odds of achieving excellent/good hemostasis (odds ratio [OR] 1.60; 95% CI, 1.00-2.56; p = 0.048) compared with PCCs (81.8%). Patients treated with andexanet (7.9%) had higher odds of a thrombotic event (OR 1.91; 95% CI, 1.13-3.20; p = 0.014) compared to those treated with PCCs (4.2%).
This study found similar results to the previous ANNEXA-1 trial but included GCS < 7 or Neurosurgery within 12 hours of enrollment, which ANNEXA did not. This study was not designed to prove non-inferiority and should not change practice, especially given the eye-watering cost of Andexanet ($25,000+) versus PCCs (~$4000-6000)…. but betting they are working on one that will.
